Sodium-coupled neutral amino acid transporter (SNAT) (SNAT)

The Sodium-coupled neutral amino acid transporter (SNAT) family, primarily represented by the SLC38 gene family, encompasses the functionally distinct System A and System N transport systems (Bröer, S., 2014, "The SLC38 family of sodium-amino acid co-transporters"). System A transporters, including SNAT1 (SLC38A1) and SNAT2 (SLC38A2), are ubiquitously expressed and mediate the sodium-dependent uptake of small neutral amino acids like alanine and glutamine to support cell growth and protein synthesis (Mackenzie, B. & Erickson, J. D., 2004, "Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family"). System N transporters, such as SNAT3 (SLC38A3) and SNAT5 (SLC38A5), are characterized by their ability to transport glutamine, asparagine, and histidine in exchange for protons, playing a vital role in the glutamate-glutamine cycle between neurons and astrocytes and in hepatic nitrogen metabolism (Bak, L. K., et al., 2006, "The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer"). In many malignancies, these transporters are overexpressed to facilitate the high glutamine flux required for tumor metabolism, making them significant targets for therapeutic intervention (Wang, Q., et al., 2015, "Targeting amino acid transport in cancer"). Pharmacological inhibition of these systems, such as with the System A-specific inhibitor alpha-methylaminoisobutyric acid (MeAIB), aims to starve cancer cells of essential nutrients (Pochini, L., et al., 2014, "SLC transporters: Structure, function and drug targets"). However, targeting these transporters presents challenges due to their essential roles in brain neurotransmission and liver detoxification of ammonia (Häussinger, D., et al., 2010, "Hepatic encephalopathy").

Other names

SLC38 familySystem N transportersSystem A transportersNeutral amino acid transportersSNATsSystem N/A

Inhibition of sodium-dependent neutral amino acid uptake to disrupt metabolic pathways in cancer cells or modulate neurotransmitter cycling.